Skip to main content
OpenTrials
Completed

NCT Number: NCT00649428

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Total Skin & Beauty Dermatology Center, PC, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is at least 18 years of age
  • Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol
  • Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol
  • Ability to comply with the study requirements
  • Negative pregnancy test (Females)
  • Healthy post-auricular skin for biopsy

Exclusion criteria

  • Excessive dermatochalasis of the treatment area
  • Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart
  • Total area to be treated exceeds 20 cm in length
  • Physical attributes which may prevent assessment or treatment as judged by the evaluator
  • Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study
  • Previous treatment with the sponsor's product
  • History of active autoimmune disease or organ transplantation
  • Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)
  • Active or chronic skin disease
  • Known genetic disorders affecting fibroblasts or collagen
  • Active systemic infection
  • Requires chronic antibiotic or steroidal therapy
  • Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study
  • Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects
  • Known allergic reactions to agents used in preparation of treatment
  • Excessive exposure to sun without adequate sun protection

Treatment and study plan

Autologous Human Fibroblast (azficel-T)

Biological
  • Collection of 3 mm post auricular skin punch biopsies.
  • Three injection treatments administered 5 ± 1 weeks apart on each side of the face.

Other names: LAVIV

Placebo

Biological
  • Collection of 3 mm post auricular skin punch biopsies.
  • Three injection visits administered 5 ± 1 weeks apart on each side of the face.

Primary outcomes

  1. Subject Wrinkle Assessment Responders

    Time frame: Baseline (prior to first treatment) and 6 months post final treatment

    A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.

  2. Evaluator Wrinkle Severity Assessment Responders

    Time frame: Baseline (prior to first treatment) and 6 months after last treatment

    A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.

Secondary outcomes

  1. Subject Wrinkle Assessment Responders

    Time frame: Baseline (prior to first treatment) compared to 3rd treatment visit, 2 and 4 months post final treatment

    A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.

  2. Evaluator Wrinkle Severity Assessment Responders

    Time frame: Baseline (prior to first treatment) compared to 3rd treatment visit, 2 and 4 months post final treatment

    A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.

Sponsors and collaborators

Lead sponsor

Castle Creek Biosciences, LLC.

Industry

Registry information

Important dates

Study start
2006
Primary completion
2008
Study completion
2009
First posted
Apr 1, 2008
Registry last updated
Mar 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.